[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
July 2014

Low-Dose Interleukin 2 to Reverse Alopecia Areata

Author Affiliations
  • 1Department of Dermatology, University of Minnesota, Minneapolis
  • 2Department of Dermatology and Immunology Center, University of Minnesota, Minneapolis
JAMA Dermatol. 2014;150(7):696-697. doi:10.1001/jamadermatol.2014.510

Cytokines have long been postulated to play a role in alopecia areata (AA), and antigen-specific scalp T cells from patients with extensive AA have been found to have an intrinsic defect in the production of TH1 cytokines such as interferon gamma and interleukin 2 (IL-2).1,2 In the interesting study presented by Castela et al,3 5 patients with extensive AA were treated with low-dose IL-2, and 4 of the 5 patients attained considerable hair regrowth. This was accompanied by an increase in regulatory T (Treg) cells; cells defined by the expression of CD4, CD25, and transcription factor forkhead box P3 (FOXP3) in skin biopsy specimens; and no significant change in circulating Treg cells. Adverse effects in this study were reported to be minimal. The investigators in the Department of Dermatology at University Hospital in Nice, France, continue to enroll research participants and list this study as a clinical trial on ClinicalTrials.gov (NCT01840046).

First Page Preview View Large
First page PDF preview
First page PDF preview
×